single-stranded RNAi

Alnylam said it had decided to exercise its right to terminate the ssRNAi collaboration, thereby returning all licenses to ssiRNAi technology back to Isis and eliminating its requirement to pay research funding.

The private placement, the New Zealand-based company said, is expected to close within the next two weeks.

Work on single-stranded RNAi technology that Genesis had been conducting for its subsidiary Solirna Biosciences has also ceased, although it may restart if an existing investor provides additional financing.

Genesis said it once again needs additional financing to allow its subsidiary to demonstrate in vivo proof of principle for its ssRNAi, a milestone that will trigger additional funding by a key investor.

As reported by RNAi News earlier this month, the long-struggling Genesis recently received a commitment from Japanese biotech firm MediBic Group to invest up to NZ$1 million ($750,000) in the planned subsidiary, Solirna BioSciences.

According to Genesis, the primary investor in the subsidiary is Japan's MediBic Group, which is primarily a pharmacogenomics firm but has made investments in RNAi drug shop Intradigm.

Genesis said that it has received a commitment from an undisclosed group for an investment in the subsidiary, which would develop its single-stranded RNAi technology. But with about two months worth of cash in the bank, the company is asking shareholders to make new equity investments.

The cash-strapped shop is betting that such a unit would embolden investors to back Genesis' ssRNAi technology independent of the company's other RNAi programs.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.